Literature DB >> 23486748

Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia.

Borja García-Bueno1, Miquel Bioque, Karina S Mac-Dowell, M Fe Barcones, Monica Martínez-Cengotitabengoa, Laura Pina-Camacho, Roberto Rodríguez-Jiménez, Pilar A Sáiz, Carmen Castro, Amalia Lafuente, Javier Santabárbara, Ana González-Pinto, Mara Parellada, Gabriel Rubio, M Paz García-Portilla, Juan A Micó, Miguel Bernardo, Juan C Leza.   

Abstract

BACKGROUND: Schizophrenia is a chronic syndrome of unknown etiology, predominantly defined by signs of psychosis. The onset of the disorder occurs typically in late adolescence or early adulthood. Efforts to study pathophysiological mechanisms in early stages of the disease are crucial in order to prompt intervention.
METHODS: Case-control study of first-episode psychotic (FEP) patients and matched controls. We recruited 117 patients during the first year after their FEP according to the DSM-IV criteria and recruited 106 gender-, race-, and age-matched controls between September 2010 and June 2011.
RESULTS: Biochemical studies carried out in peripheral mononuclear blood cells (PMBC) and plasma evidence a significant increase in intracellular components of a main proinflammatory pathway, along with a significant decrease in the anti-inflammatory ones. Multivariate logistic regression analyses identified the expression of inducible isoforms of nitric oxide synthase and cyclooxygenase in PMBC and homocysteine plasma levels as the most reliable potential risk factors and the inhibitor of the inflammatory transcription factor NFκB, IκBα, and the anti-inflammatory prostaglandin 15d-PGJ2 as potential protection factors. DISCUSSION: Taken as a whole, the results of this study indicate robust phenotypical differences at the cellular machinery level in PMBC of patients with FEP. Although more scientific evidence is needed, the determination of multiple components of pro- and anti-inflammatory cellular pathways including the activity of nuclear receptors has interesting potential as biological markers and potential risk/protective factors for FEP. Due to its soluble nature, a notable finding in this study is that the anti-inflammatory mediator 15d-PGJ2 might be used as plasmatic biomarker for first episodes of psychosis.

Entities:  

Keywords:  biomarker; first-episode psychosis; inflammatory balance; schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23486748      PMCID: PMC3932081          DOI: 10.1093/schbul/sbt001

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  58 in total

Review 1.  Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease.

Authors:  Douglas L Feinstein
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

2.  A mechanism converting psychosocial stress into mononuclear cell activation.

Authors:  Angelika Bierhaus; Jutta Wolf; Martin Andrassy; Nicolas Rohleder; Per M Humpert; Dimitri Petrov; Roman Ferstl; Maximilian von Eynatten; Thoralf Wendt; Gottfried Rudofsky; Martina Joswig; Michael Morcos; Markus Schwaninger; Bruce McEwen; Clemens Kirschbaum; Peter P Nawroth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

Review 3.  Effects of antipsychotic drugs on cytokine networks.

Authors:  T Pollmächer; M Haack; A Schuld; T Kraus; D Hinze-Selch
Journal:  J Psychiatr Res       Date:  2000 Nov-Dec       Impact factor: 4.791

4.  Elevated prenatal homocysteine levels as a risk factor for schizophrenia.

Authors:  Alan S Brown; Teodoro Bottiglieri; Catherine A Schaefer; Charles P Quesenberry; Liyan Liu; Michaeline Bresnahan; Ezra S Susser
Journal:  Arch Gen Psychiatry       Date:  2007-01

5.  Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment.

Authors:  V Arolt; M Rothermundt; K P Wandinger; H Kirchner
Journal:  Mol Psychiatry       Date:  2000-03       Impact factor: 15.992

6.  Lifetime prevalence of psychotic and bipolar I disorders in a general population.

Authors:  Jonna Perälä; Jaana Suvisaari; Samuli I Saarni; Kimmo Kuoppasalmi; Erkki Isometsä; Sami Pirkola; Timo Partonen; Annamari Tuulio-Henriksson; Jukka Hintikka; Tuula Kieseppä; Tommi Härkänen; Seppo Koskinen; Jouko Lönnqvist
Journal:  Arch Gen Psychiatry       Date:  2007-01

7.  The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress.

Authors:  José L M Madrigal; Olivia Hurtado; María A Moro; Ignacio Lizasoain; Pedro Lorenzo; Antonio Castrillo; Lisardo Boscá; Juan C Leza
Journal:  Neuropsychopharmacology       Date:  2002-02       Impact factor: 7.853

Review 8.  Intrinsic regulation of brain inflammatory responses.

Authors:  Elena Galea; Michael T Heneka; Cinzia Dello Russo; Douglas L Feinstein
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

9.  Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.

Authors:  Osamu Yokota; Seishi Terada; Takeshi Ishihara; Hanae Nakashima; Aki Kugo; Hiroshi Ujike; Kuniaki Tsuchiya; Kenji Ikeda; Yuko Saito; Shigeo Murayama; Hideki Ishizu; Shigetoshi Kuroda
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-07       Impact factor: 5.067

10.  Reduced antioxidant defense in early onset first-episode psychosis: a case-control study.

Authors:  Juan Antonio Micó; Maria Olga Rojas-Corrales; Juan Gibert-Rahola; Mara Parellada; Dolores Moreno; David Fraguas; Montserrat Graell; Javier Gil; Jon Irazusta; Josefina Castro-Fornieles; Cesar Soutullo; Celso Arango; Soraya Otero; Ana Navarro; Inmaculada Baeza; Mónica Martínez-Cengotitabengoa; Ana González-Pinto
Journal:  BMC Psychiatry       Date:  2011-02-14       Impact factor: 3.630

View more
  54 in total

Review 1.  Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.

Authors:  Masahiro Nitta; Taishiro Kishimoto; Norbert Müller; Mark Weiser; Michael Davidson; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2013-05-29       Impact factor: 9.306

Review 2.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

3.  Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis.

Authors:  C Moreno; M Parellada; K S MacDowell; B García-Bueno; B Cabrera; A González-Pinto; P Saiz; A Lobo; R Rodriguez-Jimenez; E Berrocoso; M Bernardo; J C Leza
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-03-06       Impact factor: 4.785

4.  Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis.

Authors:  Donald C Goff; Botao Zeng; Babak A Ardekani; Erica D Diminich; Yingying Tang; Xiaoduo Fan; Isaac Galatzer-Levy; Chenxiang Li; Andrea B Troxel; Jijun Wang
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

Review 5.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

6.  Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness.

Authors:  Daniel Bergé; Anna Mané; Tyler A Lesh; Miquel Bioque; Fe Barcones; Ana Maria Gonzalez-Pinto; Mara Parellada; Eduard Vieta; Josefina Castro-Fornieles; Roberto Rodriguez-Jimenez; Maria Paz García-Portilla; Judith Usall; Cameron S Carter; Bibiana Cabrera; Miguel Bernardo; Joost Janssen
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

7.  Physical Illnesses Before Diagnosed as Schizophrenia: A Nationwide Case-Control Study.

Authors:  Yi-Lung Chen; Chun-Hung Pan; Chi-Kang Chang; Pao-Huan Chen; Hu-Ming Chang; Ming-Hong Tai; Sheng-Shiang Su; Shang-Ying Tsai; Chiao-Chicy Chen; Chian-Jue Kuo
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

8.  Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Authors:  Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

9.  Risperidone Ameliorates Prefrontal Cortex Neural Atrophy and Oxidative/Nitrosative Stress in Brain and Peripheral Blood of Rats with Neonatal Ventral Hippocampus Lesion.

Authors:  Hiram Tendilla-Beltrán; Silvia Meneses-Prado; Rubén Antonio Vázquez-Roque; Miguel Tapia-Rodríguez; Andrea Judith Vázquez-Hernández; Heriberto Coatl-Cuaya; David Martín-Hernández; Karina S MacDowell; Linda Garcés-Ramírez; Juan C Leza; Gonzalo Flores
Journal:  J Neurosci       Date:  2019-09-13       Impact factor: 6.167

10.  Inflammatory molecular signature associated with infectious agents in psychosis.

Authors:  Lindsay N Hayes; Emily G Severance; Jeffrey T Leek; Kristin L Gressitt; Cathrin Rohleder; Jennifer M Coughlin; F Markus Leweke; Robert H Yolken; Akira Sawa
Journal:  Schizophr Bull       Date:  2014-04-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.